Risk factors of hyperammonemia in patients with epilepsy under valproic acid therapy

Medicine (United States)

Volumn 93, Issue 11, 2014, Pages e66-

  Tseng, Yu Lung ^a   Huang, Chi Ren ^a   Lin, Chih Hsiang ^a   Lu, Yan Ting ^a   Lu, Cheng Hsien ^a   Chen, Nai Ching ^a   Chang, Chiung Chih ^a   Chang, Wen Neng ^a   Chuang, Yao Chung ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; AMMONIA; ANTICONVULSIVE AGENT; ARIPIPRAZOLE; CARBAMAZEPINE; GAMMA GLUTAMYLTRANSFERASE; LIVER ENZYME; NEUROLEPTIC AGENT; PALIPERIDONE; PHENOBARBITAL; PHENYTOIN; QUETIAPINE; RISPERIDONE; VALPROIC ACID;

ADULT; AGED; AMMONIA BLOOD LEVEL; ARTICLE; ATAXIA; BLOOD SAMPLING; CONSCIOUSNESS DISORDER; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE INCREASE; EPILEPSY; FATIGUE; FEMALE; GENDER; HUMAN; HYPERAMMONEMIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; RISK FACTOR; SOMNOLENCE; ADOLESCENT; AGE; BLOOD; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; DRUG INTERACTION; ENZYME INDUCTION; ENZYMOLOGY; LIVER; MIDDLE AGED; PROSPECTIVE STUDY; SEX DIFFERENCE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; AMMONIA; ANTICONVULSANTS; ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; ENZYME INDUCTION; EPILEPSY; FEMALE; HUMANS; HYPERAMMONEMIA; LIVER; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; VALPROIC ACID; YOUNG ADULT;

EID: 84908314319     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000000066     Document Type: Article

References (32)

1. Dreifuss FE, Langer DH. Side effects of valproate. Am J Med. 1988;84:34-41.
2. Nicolai J, Carr RB. The measurement of ammonia blood levels in patients taking valproic acid: looking for problems where they do not exist?Epilepsy Behav. 2008;12:494-496.
3. Murphy JV, Marquardt K. Asymptomatic hyperammonemia in patients receiving valproic acid. Arch Neurol. 1982;39:591-592.
4. Haidukewych D, John G, Zielinski JJ, et al. Chronic valproic acid therapy and incidence of increases in venous plasma ammonia. Ther Drug Monit. 1985;7:290-294.
5. Kugoh T, Yamamoto M, Hosokawa K. Blood ammonia level during valproic acid therapy. Jpn J Psychiatry Neurol. 1986;40:663-668.
6. Yamamoto Y, Takahashi Y, Suzuki E, et al. Risk factors for hyperammonemia associated with valproic acid therapy in adult epilepsy patients. Epilepsy Res. 2012;101:202-209.
7. Auron A, Brophy PD. Hyperammonemia in review: pathophysiology, diagnosis, and treatment. Pediatr Nephrol. 2012;27:207-222.
8. Hung CC, Li TM, Wei IH, et al. The real mechanism of VPA-induced hyperammonemia remains unknown. Gen Hosp Psychiatry. 2011;33:84.
9. Aires CC, van Cruchten A, Ijlst L, et al. New insights on the mechanisms of valproate-induced hyperammonemia: inhibition of hepatic N-acetylglutamate synthase activity by valproyl-CoA. J Hepatol. 2011;55:426-434.
10. Yamamoto Y, Takahashi Y, Imai K, et al. Risk factors for hyperammonemia in pediatric patients with epilepsy. Epilepsia. 2013;54:983-989.
11. Sharma S, Gulati S, Kabra M, et al. Blood ammonia levels in epileptic children on 2 dose ranges of valproic acid monotherapy: a cross-sectional study. J Child Neurol. 2011;26:109-112.
12. Hamed SA, Abdella MM. The risk of asymptomatic hyperammonemia in children with idiopathic epilepsy treated with valproate: relationship to blood carnitine status. Epilepsy Res. 2009;86:32-41.
13. Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia. 1989;30:389-399.
14. Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010;51:1069-1077.
15. Chuang YC, Chuang HY, Lin TK, et al. Effects of long-term antiepileptic drug monotherapy on vascular risk factors and atherosclerosis. Epilepsia. 2012;53:120-128.
16. Belcastro V, Striano P, Gorgone G, et al. Hyperhomocysteinemia in epileptic patients on new antiepileptic drugs. Epilepsia. 2010;51:274-279.
17. Liu KT, Yang SC, Yeh IJ, et al. Transient hyperammonemia associated with postictal state in generalized convulsion. Kaohsiung J Med Sci. 2011;27:453-456.
18. Altunbasak S, Baytok V, Tasouji M, et al. Asymptomatic hyperammonemia in children treated with valproic acid. J Child Neurol. 1997;12:461-463.
19. Wyllie E, Wyllie R, Rothner AD, et al. Valproate-induced hyperammonemia in asymptomatic children. Cleve Clin Q. 1983;50:275-277.
20. van den Broek MP, Sikma MA, Ververs TF, et al. Severe valproic acid intoxication: case study on the unbound fraction and the applicability of extracorporeal elimination. Eur J Emerg Med. 2009;16:330-332.
21. Velioglu SK, Gazioglu S. Non-convulsive status epilepticus secondary to valproic acid-induced hyperammonemic encephalopathy. Acta Neurol Scand. 2007;116:128-132.
22. Kifune A, Kubota F, Shibata N, et al. Valproic acid-induced hyperammonemic encephalopathy with triphasic waves. Epilepsia. 2000;41:909-912.
23. Hamer HM, Knake S, Schomburg U, Rosenow F. Valproate-induced hyperammonemic encephalopathy in the presence of topiramate. Neurology. 2000;54:230-232.
24. Carlson T, Reynolds CA, Caplan R. Case report: valproic acid and risperidone treatment leading to development of hyperammonemia and mania. J Am Acad Child Adolesc Psychiatry. 2007;46:356-361.
25. Patsalos PN, Froscher W, Pisani F, van Rijn CM. The importance of drug interactions in epilepsy therapy. Epilepsia. 2002;43:365-385.
26. Yagi M, Nakamura T, Okizuka Y, et al. Effect of CPS14217C>A genotype on valproic-acid-induced hyperammonemia. Pediatr Int. 2010;52:744-748.
27. Knudsen JF, Sokol GH, Flowers CM. Adjunctive topiramate enhances the risk of hypothermia associated with valproic acid therapy. J Clin Pharm Ther. 2008;33:513-519.
28. Longin E, Teich M, Koelfen W, Konig S. Topiramate enhances the risk of valproate-associated side effects in three children. Epilepsia. 2002;43:451-454.
29. Carr RB, Shrewsbury K. Hyperammonemia due to valproic acid in the psychiatric setting. Am J Psychiatry. 2007;164:1020-1027.
30. Holroyd S, Overdyke JT. Hyperammonemia associated with valproic acid use in elderly psychiatric patients. J Neuropsychiatry Clin Neurosci. 2012;24:372-374.
31. Lippi G, Montagnana M, Salvagno GL, Guidi GC. Influence of stable, long-term treatment with phenobarbital on the activity of serum alanine aminotransferase and gamma-glutamyltransferase. Br J Biomed Sci. 2008;65:132-135.
32. Aldenhovel HG. The influence of long-term anticonvulsant therapy with diphenylhydantoin and carbamazepine on serum gamma-glutamyltransferase, aspartate aminotransferase, alanine aminotransferase and alkaline phosphatase. Eur Arch Psychiatry Neurol Sci. 1988;237:312-316